このエントリーをはてなブックマークに追加
ID 56178
JaLCDOI
FullText URL
Thumnail 72_4_401.pdf 2.12 MB
Author
Wada, Nozomu Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Ikeda, Fusao Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mori, Chizuru Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takaguchi, Koichi Department of Internal Medicine, Kagawa Prefectural Central Hospital
Fujioka, Shin-ichi Department of Internal Medicine, Okayama Saiseikai General Hospital
Kobashi, Haruhiko Department of Internal Medicine, Okayama Red Cross Hospital
Morimoto, Yoichi Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Kariyama, Kazuya Department of Liver Disease Center, Okayama City Hospital
Sakaguchi, Kosaku Department of Internal Medicine, Fukuyama City Hospital
Hashimoto, Noriaki Department of Internal Medicine, Mihara Red Cross Hospital
Moriya, Akio Department of Gastroenterology, Mitoyo General Hospital
Kawaguchi, Mitsuhiko Department of Internal Medicine, Kawaguchi Medical Clinic
Miyatake, Hirokazu Department of Internal Medicine, Hiroshima City Hospital
Hagihara, Hiroaki Department of Gastroenterology, Sumitomo Besshi Hospital
Kubota, Junichi Department of Internal Medicine, Tajiri Hospital
Takayama, Hiroki Department of Gastroenterology, Tsuyama Central Hospital
Takeuchi, Yasuto Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yasunaka, Tetsuya Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takaki, Akinobu Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Iwasaki, Yoshiaki Health Service Center, Okayama University
Okada, Hiroyuki Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Abstract
Daclatasvir (DCV) + asunaprevir (ASV) combination therapy has become available for patients with hepatitis C virus (HCV) serogroup 1 infection. We studied the efficacy of this therapy by focusing on the factors associated with sustained virological responses (SVR) including resistance-associated variants (RAVs) and mixed infection of different HCV genotypes. We enrolled 951 HCV serogroup 1-positive patients who received this combination therapy at our hospital or affiliated hospitals. The presence of RAVs in non-structural (NS) regions 3 and 5A was analyzed by direct sequencing. HCV genotypes were determined by PCR with genotype-specific primers targeting HCV core and NS5B regions. SVR was achieved in 91.1% of patients. Female sex, age > 70 years, and RAVs were significantly associated with non-SVR (p<0.01 for all). Propensity score-matching results among the patients without RAVs regarding sex, age, and fibrosis revealed that mixed HCV infection determined by HCV NS5B genotyping showed significantly lower SVR rates than 1B-mono infection (p=0.02). Female sex and RAVs were significant factors associated with treatment failure of this combination therapy for patients with HCV serogroup 1 infection. Mixed HCV infection other than 1B-mono infection would be useful for predicting treatment failure.
Keywords
mixed genotype
daclatasvir
asunaprevir
HCV
serogrouping 1 infection
Amo Type
Original Article
Published Date
2018-08
Publication Title
Acta Medica Okayama
Volume
volume72
Issue
issue4
Publisher
Okayama University Medical School
Start Page
401
End Page
406
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2018 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID